Metabolic Syndrome


Metabolic Syndrome encompasses a constellation of conditions that collectively elevate the risk of Heart Disease, Stroke, Type 2 Diabetes, and mortality. It reflects the widespread obesity epidemic, affecting two out of three U.S. adults. As defined by the American Heart Association (AHA) and the National Institutes of Health (NIH), Metabolic Syndrome comprises elevated blood pressure (above 130/85 mm Hg), elevated serum glucose (above 100mg/dl), increased waist circumference (above 40 inches or 102 cm for men, and above 35 inches or 88 cm for women), decreased "good" HDL (under 40 mg/dl for men and under 50 mg/dl for women), and increased serum triglycerides (above 150mg/dl).

Clinical trials have demonstrated that Tocotrienols can effectively improve many of these markers, offering potential benefits for the one in three Americans affected by Metabolic Syndrome. Tocotrienols have been shown to enhance aminotransferase levels and reduce several inflammatory and oxidative stress markers in Non-Alcoholic Fatty Liver Disease (NAFLD). They inhibit adipogenesis, the formation of adipocytes (fat cells from stem cells), leading to reduced body weight and fat mass in animal studies by regulating lipid metabolism and fatty acid biosynthesis pathways. Additionally, Tocotrienols decrease the expression of transcription factors, molecules that inhibit adipogenesis and promote apoptosis (cell death) of adipocytes (fat cells). In diabetic models, Tocotrienols enhance glucose homeostasis by suppressing cellular and tissue inflammation and oxidative stress.

References